CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 14 clinical trials at NIH that match your search criteria

Cancer by type/disease: Kidney (Renal Cell) Cancer

Trial and Protocol Number Kidney (Renal Cell) Cancer	Principal Investigator	Referral Contact
Phase II
A Phase II Study of Bevacizumab in Combination With Ixabepilone in Subjects With Advanced Renal Cell Carcinoma NCI-09-C-0057	Olivier Rixe 301-435-2279	Maureen Edgerly 301-435-5604 edgerlym@mail.nih.gov
A Phase II Study of ZD6474 (Vandetanib) in Subjects With Advanced Clear Cell Renal Carcinoma NCI-08-C-0039	W. Marston Linehan 301-496-6353	David Draper 301-435-5614 draperd@mail.nih.gov
A Phase II Study of the c-Met RTK Inhibitor GSK 1363089 (Formerly XL880) in Subjects With Papillary Renal-Cell Carcinoma (PRC) NCI-07-C-0121	Ramaprasad Srinivasan 301-496-6353	Martha Ninos 301-435-8897 mninos@mail.nih.gov
A Phase II Clinical Trial of BMS-247550 (NSC 710428), an Epothilone B Analog, in Renal Cell Carcinoma NCI-02-C-0130	Antonio Tito Fojo 301-402-1357	Maureen Edgerly 301-435-5604 edgerlym@mail.nih.gov
Phase I/II
Phase I/II Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor NCI-09-C-0092	James C. Yang 301-496-1574	June A. Kryk 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells NCI-08-C-0088	Daniel Fowler 301-435-8641	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov

Trial and Protocol Number Leiomyomatosis	Principal Investigator	Referral Contact
No Phase
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer NCI-03-C-0066	W. Marston Linehan 301-496-6353

Trial and Protocol Number Melanoma	Principal Investigator	Referral Contact
Phase I
A Phase I Study of Subcutaneous "CYT 107" (Interleukin-7) in Refractory Metastatic Melanoma or Renal Cell Carcinoma NCI-07-C-0114	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov

Trial and Protocol Number Solid Tumor	Principal Investigator	Referral Contact
Phase II
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes NCI-08-C-0121	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase I
A Phase I, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects With Refractory Solid Tumors Associated With EphA2 Expression NCI-09-C-0168	Elise C. Kohn 301-402-2726	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors NCI-09-C-0019	Elise C. Kohn 301-402-2726	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I Investigation of IL-12/Pulse IL-2 in Adults With Advanced Solid Tumors NCI-00-C-0121	John E. Janik 301-402-2913	Debbie Draper 301-435-8525 draperde@mail.nih.gov

Trial and Protocol Number Von Hippel-Lindau	Principal Investigator	Referral Contact
Phase II
A Phase II Study of ZD6474 (Vandetanib) in Patients With Von Hippel Lindau Disease and Renal Tumors NCI-08-C-0020	W. Marston Linehan 301-496-6353	Sarah Fowler 301-435-6255 fowlers@mail.nih.gov
No Phase
Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders NCI-89-C-0086	W. Marston Linehan 301-496-6353

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.